Takeda
FREE Daily Email Newsletter
Amag Slumps on Ferahame Recall in Switzerland
May 23, 2013 8:43 am | News | CommentsAmag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland. Amag said four patients experienced severe allergic reactions to the drug, and one of those patients died. That batch was sold only in Switzerland, and the recall doesn't affect any other countries.
Takeda Launches New Subsidiary in Ecuador
March 21, 2013 7:56 am | News | CommentsTakeda Pharmaceuticals International GmbH, today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey
March 4, 2013 7:59 am | News | CommentsMore than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Takeda and Resolve Therapeutics Enter Autoimmune Partnership
February 28, 2013 7:56 am | News | CommentsTakeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.
Amgen Rises on Recall of Affymax Anemia Drug
February 26, 2013 8:07 am | News | CommentsShares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients. Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection
February 25, 2013 7:51 am | News | CommentsAffymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.
Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals
February 8, 2013 7:55 am | News | CommentsSucampo Pharmaceuticals, Inc. today announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Anchen Pharmaceuticals, Inc., Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.
Takeda to Acquire Envoy Therapeutics
November 6, 2012 3:31 am | News | CommentsTakeda Pharmaceutical Company Limited (Takeda) and Envoy Therapeutics Inc. (Envoy) jointly announced today that Takeda’s wholly-owned subsidiary, Takeda America Holdings, Inc. and Envoy have entered into a definitive agreement for Takeda America Holdings to acquire Envoy.
Takeda to Acquire LigoCyte Pharmaceuticals
October 5, 2012 4:02 am | News | CommentsTakeda Pharmaceutical Company Limited and LigoCyte Pharmaceuticals, Inc. jointly announced today that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and LigoCyte Pharmaceuticals, Inc. have entered into a definitive agreement for Takeda to acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.
Takeda Completes its Russian Pharmaceutical Manufacturing Facility
September 11, 2012 3:58 am | News | CommentsTakeda Pharmaceutical International GmbH today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia. The Company has invested approximately 75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014.
Takeda Completes Acquisition of URL Pharma, Inc.
June 4, 2012 4:29 am | News | CommentsTakeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., jointly announced that Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. for an upfront payment of $800 million.
Canadian Study Suggest Diabetes Drug Increases Risk of Bladder Cancer
June 1, 2012 4:15 am | by Helen Branswell, THE CANADIAN PRESS | News | CommentsTORONTO — A new study adds further weight to the argument that people who use the diabetes drug Actos are at higher risk of developing bladder cancer.
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
May 25, 2012 4:05 am | News | CommentsTakeda Pharmaceutical Company Limited and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. today jointly announced that both parties have signed an agreement whereby Takeda Farmacêutica Brasil Ltda., a wholly-owned subsidiary of Takeda, aims to acquire Multilab.
Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone
April 26, 2012 4:28 am | News | CommentsTakeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant in the U.S.
April 20, 2012 4:11 am | News | CommentsPar Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals LLC to acquire Handa's ANDA for dexlansoprazole capsules, the generic version of Takeda's Dexilant.
Takeda to Buy URL Pharma for $800M Upfront
April 11, 2012 3:59 am | by The Associated Press | News | CommentsJapanese drugmaker Takeda Pharmaceutical Co. Ltd. said Wednesday it will pay $800 million upfront to buy the privately held U.S. gout treatment maker URL Pharma Inc.
Takeda Reports Positive Data from Late-Stage Trial
February 21, 2012 4:15 am | by Lianne Dane | News | CommentsTakeda announced Monday that vedolizumab met its endpoints in both phases of the GEMINI I trial involving patients with moderately to severely active ulcerative colitis.
U.S. Regulators Approve Subcutaneous Version of Takeda’s Velcade
January 24, 2012 4:20 am | by Lianne Dane | News | CommentsTakeda on Monday announced that the FDA approved a label update for Velcade (bortezomib) to include subcutaneous administration of the drug in all approved indications.
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
January 18, 2012 2:59 am | News | CommentsTakeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth.
Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
December 21, 2011 3:26 am | News | CommentsTakeda Pharmaceutical Company Limited and Intellikine, Inc. today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.
Takeda Trims Annual Profit Forecast; Reports Drop in Net Income, Sales
November 4, 2011 6:45 am | by Matthew Dennis | News | CommentsTakeda announced Friday a reduction of its full-year net income forecast by 32 percent due to costs related to the 9.6-billion euro ($13.3 billion) takeover of Nycomed and the stronger Japanese currency.
Takeda Completes Acquisition and Names New CEO of Nycomed
September 30, 2011 4:31 am | News | CommentsTakeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary
Affymax Receives $10M Payment from Takeda Pharma
August 10, 2011 6:09 am | by the Associated Press | News | CommentsAffymax Inc. received a $10 million milestone payment from partner Takeda Pharmaceutical Co., the company said Wednesday, after federal regulators accepted an application for the potential anemia treatment peginesatide.
Takeda Resubmits NDAs for Diabetes Treatment
July 26, 2011 4:33 am | News | CommentsTakeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications (NDA) to the FDA for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.
EMA Recommends Cancer Risk Warning for Takeda's Actos
July 22, 2011 5:28 am | by Matthew Dennis | News | CommentsThe European Medicines Agency recommended Thursday that a warning be added to the label of Takeda's Actos (pioglitazone) regarding a "small increased risk of bladder cancer."
